CA3216005A1 - Fc variant with enhanced affinity to fc receptors and improved thermal stability - Google Patents

Fc variant with enhanced affinity to fc receptors and improved thermal stability Download PDF

Info

Publication number
CA3216005A1
CA3216005A1 CA3216005A CA3216005A CA3216005A1 CA 3216005 A1 CA3216005 A1 CA 3216005A1 CA 3216005 A CA3216005 A CA 3216005A CA 3216005 A CA3216005 A CA 3216005A CA 3216005 A1 CA3216005 A1 CA 3216005A1
Authority
CA
Canada
Prior art keywords
amino acid
acid position
polypeptide
domain
effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216005A
Other languages
English (en)
French (fr)
Inventor
Jochen Beninga
Beatrice Cameron
Ingo Focken
Sagar KATHURIA
Christian Lange
Alessandro Masiero
Sunghae PARK
Bodo TILLMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA3216005A1 publication Critical patent/CA3216005A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3216005A 2021-05-27 2022-05-27 Fc variant with enhanced affinity to fc receptors and improved thermal stability Pending CA3216005A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163193665P 2021-05-27 2021-05-27
US63/193,665 2021-05-27
EP21315127 2021-07-15
EP21315127.7 2021-07-15
PCT/IB2022/055019 WO2022249146A1 (en) 2021-05-27 2022-05-27 Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY

Publications (1)

Publication Number Publication Date
CA3216005A1 true CA3216005A1 (en) 2022-12-01

Family

ID=82358573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216005A Pending CA3216005A1 (en) 2021-05-27 2022-05-27 Fc variant with enhanced affinity to fc receptors and improved thermal stability

Country Status (12)

Country Link
US (2) US12297273B2 (https=)
EP (1) EP4347640A1 (https=)
JP (1) JP2024522092A (https=)
KR (1) KR20240015093A (https=)
AU (1) AU2022282666A1 (https=)
BR (1) BR112023022584A2 (https=)
CA (1) CA3216005A1 (https=)
CO (1) CO2023016432A2 (https=)
IL (1) IL308733A (https=)
MX (1) MX2023014100A (https=)
TW (1) TW202306584A (https=)
WO (1) WO2022249146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7312181B2 (en) 2005-04-08 2007-12-25 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2825557B1 (en) * 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EA201891753A1 (ru) * 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
AR108963A1 (es) 2016-04-13 2018-10-17 Merial Inc Dispositivo de inyección con mecanismo de accionamiento para administrar múltiples formulaciones líquidas, tales como vacunas
CN108218998A (zh) * 2017-12-31 2018-06-29 武汉班科生物技术股份有限公司 一种突变型人源IgG的Fc片段及其制备方法与应用
IL276286B2 (en) 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
JP7792330B2 (ja) * 2019-09-03 2025-12-25 アムジエン・インコーポレーテツド Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法

Also Published As

Publication number Publication date
AU2022282666A1 (en) 2024-01-18
IL308733A (en) 2024-01-01
BR112023022584A2 (pt) 2024-01-09
CO2023016432A2 (es) 2023-12-11
US20230077531A1 (en) 2023-03-16
MX2023014100A (es) 2023-12-11
US20250376526A1 (en) 2025-12-11
KR20240015093A (ko) 2024-02-02
TW202306584A (zh) 2023-02-16
US12297273B2 (en) 2025-05-13
WO2022249146A1 (en) 2022-12-01
JP2024522092A (ja) 2024-06-11
EP4347640A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
AU2018344416B2 (en) IgG1 Fc mutants with ablated effector functions
AU2019212638B2 (en) Fc variants with enhanced binding to FcRn and prolonged half-life
JP6898303B2 (ja) Ｓｉｒｐ−アルファドメインまたはそのバリアントを有する構築物
RU2570633C2 (ru) Три- или тетраспецифические антитела
JP5768147B2 (ja) 一価抗原結合タンパク質
JP2019167363A (ja) ＦｃＲｎ結合が無効となった抗ＩＧＦ−１Ｒ抗体及び血管性眼疾患の処置におけるそれらの使用
US20210024620A1 (en) Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
US20230235090A1 (en) Bispecific antibody and use thereof
EP4495142A2 (en) Bispecific antigen binding construct
US20250376526A1 (en) Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
AU2020358898B2 (en) Hybrid antibody
CN115151567A (zh) 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化
US20250206824A1 (en) GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
CN117377685A (zh) 具有对Fc受体的增强的亲和力和改善的热稳定性的Fc变体
US20240360233A1 (en) Anti-tslpr (crlf2) antibodies
US20250154262A1 (en) Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250522

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250522